NeuroVision

Groundbreaking AI Platform Is Transforming Brain Health

About this Event

NeuroVision is redefining how we prevent, diagnose, and treat Alzheimer’s and other neurological conditions.

Today, 1 in 3 Americans dies with Alzheimer’s or dementia. And once diagnosed, it can take 10 months or more to see a neurologist—time during which the disease continues to progress.

NeuroVision’s AI-driven BrainHealth Platform partners with primary care physicians to close that gap. Within two weeks, patients can access comprehensive risk assessment, cognitive testing, biomarker and genetic analysis, a neurology consult, and science-backed lifestyle programs. This enables timely intervention—whether fast-tracking candidates for new treatments or addressing other causes of cognitive decline (like B12 deficiency or thyroid dysfunction).

Their hybrid revenue model combines insurance reimbursements with subscription-based lifestyle memberships, creating a long-tail recurring stream.

Register now to watch this webinar with NeuroVision CEO, Steven Verdooner, to hear about their commercial pilot which launched last year and how the company expects to generate $6M in revenue in 2025 and is projecting $39M, reaching breakeven by Q4 2026.

Video On Demand

– Recorded

April 30

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.